1. Latest News
  2. Submit Press Release

Quantitate biotherapeutic drug-targets through Pharmacokinetic & pharmacodynamic

Join SMi Group in January 2013 London to discover the latest developments in compound screening and toxicity testing to companion diagnostic assays at our 6th annual Biomarkers Summit.

Nov. 28, 2012 - PRLog -- This year’s event will feature a wide variety of speakers and presentations, offering delegates the perfect opportunity to discuss new opportunities and strategies to accelerate go/no-go decision making in early and clinical development.

SMi is pleased to confirm Andrew Warren, Director, PK/PD/Immunogenicity Bioanalysis, Novartis as a speaker of the event.

He will discuss how to deliver safe starting and therapeutically relevant escalation doses for human studies, as well as target-mediated drug disposition and Assaying captured drug-target complexes

Attending will enable delegates to:

Accelerate companion diagnostics development for therapeutic indications

Validate and deliver biomarkers for patient selection during clinical trials

Implement sub-grouping in patient segmentation studies

Utilise revised FDA regulatory guidelines to aid product development

Optimise reimbursement strategies for diagnostics

Maximise biomarker identification using epigenetic and metabolomic insights

For more information visit http://www.smi-online.co.uk/goto/biomarkers-summit63.asp alternatively contact Cem Tuna on +44 0 207 827 6736 or email on ctuna@smi-online.co.uk

--- End ---

Click to Share

Contact Email:
***@smi-online.co.uk Email Verified
Source:SMi Group
Location:United Kingdom
Industry:Biotech, Event
Tags:Pharmacodynamics, Pharmacokinetic, Biomarker
Verified Account Email Address
Verified Account Phone Number

Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Latest Press Releases By “


Trending News...

Like PRLog?
Click to Share